Suppr超能文献

常规筛查接受性别肯定激素治疗的跨性别和性别多样化成年人:一项叙述性综述。

Routine Screening for Transgender and Gender Diverse Adults Taking Gender-Affirming Hormone Therapy: a Narrative Review.

机构信息

Division of Endocrinology, Metabolism & Diabetes, Department of Medicine, University of Colorado, Anschutz Medical Campus, 12801 E 17th Ave, Aurora, CO, 80045, USA.

Department of Endocrinology, Medicine Service, Rocky Mountain Regional Veterans Affairs Medical Center, VA Eastern Colorado Health Care System, Aurora, 80045, CO, USA.

出版信息

J Gen Intern Med. 2021 May;36(5):1380-1389. doi: 10.1007/s11606-021-06634-7. Epub 2021 Feb 5.

Abstract

Despite the growing number of adult transgender and gender diverse (TGD) patients seeking health services, there are many unknowns regarding how routine screening recommendations should be applied to TGD persons receiving gender-affirming hormone therapy (GAHT). Patients taking GAHT may have disease risks that differ from what is expected based on their sex assigned at birth or affirmed gender identity. We discuss two patient cases, one transgender man and one transgender woman who present for routine medical care, to review several conditions that may be impacted by the hormones utilized in masculinizing and feminizing GAHT and for which screening recommendations are available for TGD adults: cardiovascular risk factors, osteoporosis, breast cancer, cervical cancer, and prostate cancer. We reviewed the TGD-specific screening recommendations from several major medical organizations and programs and found them to be largely based upon expert opinion due to a lack of evidence. The goal of this narrative review is to assist healthcare professionals in counseling and screening their TGD patients when and where appropriate. Not all TGD adults have the ability or need to receive routine medical care from a specialized TGD health clinic; therefore, it is essential for all healthcare professionals involved in routine and gender-affirming care to have knowledge about these conditions and screenings.

摘要

尽管越来越多的成年跨性别和性别多样化(TGD)患者寻求医疗服务,但对于如何将常规筛查建议应用于接受性别肯定激素治疗(GAHT)的 TGD 患者,仍有许多未知之处。接受 GAHT 的患者可能存在与基于出生时分配的性别或确认的性别认同所预期的不同的疾病风险。我们讨论了两个患者病例,一个是跨性别男性,一个是跨性别女性,他们因常规医疗护理就诊,以回顾几种可能受到用于男性化和女性化 GAHT 的激素影响的疾病,以及针对 TGD 成年人的可用筛查建议:心血管危险因素、骨质疏松症、乳腺癌、宫颈癌和前列腺癌。我们回顾了几个主要医疗组织和项目的 TGD 特定筛查建议,发现它们主要基于专家意见,因为缺乏证据。本叙述性综述的目的是帮助医疗保健专业人员在适当的时候为 TGD 患者提供咨询和筛查。并非所有 TGD 成年人都有能力或需要从专门的 TGD 健康诊所获得常规医疗护理;因此,所有参与常规和性别肯定护理的医疗保健专业人员都必须了解这些疾病和筛查。

相似文献

1
Routine Screening for Transgender and Gender Diverse Adults Taking Gender-Affirming Hormone Therapy: a Narrative Review.
J Gen Intern Med. 2021 May;36(5):1380-1389. doi: 10.1007/s11606-021-06634-7. Epub 2021 Feb 5.
3
Clinicians in the Veterans Health Administration initiate gender-affirming hormone therapy in concordance with clinical guideline recommendations.
Front Endocrinol (Lausanne). 2024 May 10;15:1086158. doi: 10.3389/fendo.2024.1086158. eCollection 2024.
4
Barriers and Facilitators to Gender-affirming Hormone Therapy in the Veterans Health Administration.
Ann Behav Med. 2023 Nov 16;57(12):1014-1023. doi: 10.1093/abm/kaad035.
5
Bone health in transgender assigned female at birth people: effects of gender-affirming hormone therapy and gonadectomy.
Front Endocrinol (Lausanne). 2024 Sep 26;15:1416121. doi: 10.3389/fendo.2024.1416121. eCollection 2024.
7
Breast care considerations for transgender and gender-diverse patients.
Womens Health (Lond). 2024 Jan-Dec;20:17455057241289706. doi: 10.1177/17455057241289706.
8
Laboratory Changes During Gender-Affirming Hormone Therapy in Transgender Adolescents.
Pediatrics. 2024 May 1;153(5). doi: 10.1542/peds.2023-064380.
9
Androgenetic alopecia incidence in transgender and gender diverse populations: A retrospective comparative cohort study.
J Am Acad Dermatol. 2023 Sep;89(3):504-510. doi: 10.1016/j.jaad.2023.01.037. Epub 2023 Feb 11.
10
Reproductive health risks and clinician practices with gender diverse adolescents and young adults.
Andrology. 2021 Nov;9(6):1689-1697. doi: 10.1111/andr.13026. Epub 2021 May 24.

引用本文的文献

2
Oncological needs in transgender patients.
Clin Transl Oncol. 2025 Apr 18. doi: 10.1007/s12094-025-03917-x.
3
Immune dynamics throughout life in relation to sex hormones and perspectives gained from gender-affirming hormone therapy.
Front Immunol. 2025 Jan 16;15:1501364. doi: 10.3389/fimmu.2024.1501364. eCollection 2024.
4
Hormone therapy and cancer risks in transgender people: a systematic review.
Epidemiol Serv Saude. 2025 Jan 10;33(spe1):e2024319. doi: 10.1590/S2237-96222024v33e2024319.especial.en. eCollection 2025.
6
Cardiovascular disease risk in the transgender population.
Arch Cardiol Mex. 2023;93(Supl):26-30. doi: 10.24875/ACM.M23000091.
8
Gender-affirming hormone therapy, mental health, and surgical considerations for aging transgender and gender diverse adults.
Ther Adv Endocrinol Metab. 2023 Apr 19;14:20420188231166494. doi: 10.1177/20420188231166494. eCollection 2023.
10
Effects of Hormones on Breast Development and Breast Cancer Risk in Transgender Women.
Cancers (Basel). 2022 Dec 30;15(1):245. doi: 10.3390/cancers15010245.

本文引用的文献

3
Healthcare Policy Changes in Osteoporosis Can Improve Outcomes and Reduce Costs in the United States.
JBMR Plus. 2019 May 13;3(9):e10192. doi: 10.1002/jbm4.10192. eCollection 2019 Sep.
4
Assessing gender identity differences in cardiovascular disease in US adults: an analysis of data from the 2014-2017 BRFSS.
J Behav Med. 2020 Apr;43(2):329-338. doi: 10.1007/s10865-019-00102-8. Epub 2019 Sep 26.
6
Bone Health in the Transgender Population.
Clin Rev Bone Miner Metab. 2019 Jun;17(2):77-85. doi: 10.1007/s12018-019-09261-3. Epub 2019 Jul 2.
7
Bone Densitometry in Transgender and Gender Non-Conforming (TGNC) Individuals: 2019 ISCD Official Position.
J Clin Densitom. 2019 Oct-Dec;22(4):544-553. doi: 10.1016/j.jocd.2019.07.004. Epub 2019 Jul 10.
9
Cardiovascular Disease Risk Factors and Myocardial Infarction in the Transgender Population.
Circ Cardiovasc Qual Outcomes. 2019 Apr;12(4):e005597. doi: 10.1161/CIRCOUTCOMES.119.005597.
10
Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy.
Circulation. 2019 Mar 12;139(11):1461-1462. doi: 10.1161/CIRCULATIONAHA.118.038584.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验